Drug Profile
Hyodeoxycholic acid
Alternative Names: AHRO-001; HDCALatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AtheroNova
- Developer AtheroNova; CardioNova
- Class Antihyperlipidaemics; Cholic acids; Small molecules; Vascular disorder therapies
- Mechanism of Action Cholesterol absorption inhibitors; Gene expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Atherosclerosis(In volunteers) in Russia (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA (PO, Tablet)
- 30 Jul 2014 AtheroNova initiates the phase Ib portion of a trial in Atherosclerosis (in volunteers) in Russia (NCT01931241; 9166319)